Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer responding to systemic therapy.
Press Release|Articles|July 24, 2025
ACRO Accreditation Again Receives ISO:9001 2015 Certification
Author(s)ACRO
ACRO's Accreditation Program has completed and passed its annual surveillance by the International Standards Organization.
Advertisement
The American College of Radiation Oncology’s Accreditation Program has completed and passed its annual surveillance by the International Standards Organization (ISO). ACRO Accreditation is the only U.S. radiation oncology accrediting body to achieve ISO 9001:2015 Certification.
The ISO is a highly regarded international certification body which evaluates an organization’s processes and procedures. The program undergoes a comprehensive yearly review of its quality objectives, operations, and structure.
Advertisement
Related to this article
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence and the data that shaped his approach.
Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.
Tyler J. Wilhite, MD, discussed coordinating with rheumatology, orthopedic surgery, and primary care when treating patients with osteoarthritis with low-dose radiation therapy.
Tyler J. Wilhite, MD, discussed scaling low-dose radiation therapy for osteoarthritis from 1 patient to nearly 20 centers and the referral work behind it.
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
2
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
3
PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer
4
Cesalatamig Monotherapy Yields Responses in PD-(L)1–Resistant NSCLC
5